JSSH(000518)2018-06-19 16:00Cost Structure - The cost structure of the main products shows that the raw material cost for Interleukin increased to 54.31% in 2017 from 51.01% in 2016, a rise of 3.30%[1] - EPO's raw material cost accounted for 73.46% of its total cost in 2017, up from 71.77% in 2016, reflecting a 1.69% increase[1] - G-CSF's raw material cost decreased to 59.27% in 2017 from 60.68% in 2016, a decline of 1.41%[1] - The total raw material cost for the pharmaceutical manufacturing sector was 39,908,472.21 yuan in 2017, representing 59.77% of the total operating cost, compared to 52,730,251.48 yuan and 49.41% in 2016, marking a 10.36% increase[2] Financial Performance - The company reported a net profit attributable to the parent company of 313.50 million yuan, with a decrease of 49.83% in 2017 compared to the previous year[4] Strategic Plans - The company plans to expand its market presence and enhance product offerings through strategic acquisitions and partnerships[4] - The company is focusing on the development of new technologies and products to drive future growth[4] - The company aims to maintain a competitive edge in the pharmaceutical industry through continuous innovation and market expansion strategies[4] Operational Improvements - The company has implemented measures to address the decline in operating income and improve overall profitability[4] - The company plans to enhance the review process for periodic report preparation to improve the quality of information disclosure[7] Information Disclosure - The company has committed to ensuring accurate and transparent information disclosure in its financial reporting[1] - The company reported a total related party transaction amount of 1,142.4 million yuan, with a market price of 88.12 yuan per unit[5] - The company confirmed that the total amount of expected daily related party transactions for the reporting period is 114.25 million yuan[6] - There were no significant sales returns reported during the period[6] - The company acknowledged a data entry error due to staff negligence and expressed apologies to investors[7]